Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

1
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
1
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

50.4K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.4K
Sexually Transmitted Infections01:26

Sexually Transmitted Infections

1.5K
Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
1.5K
Immune Response Against Viral Pathogens01:29

Immune Response Against Viral Pathogens

2.4K
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
2.4K
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

2.7K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
2.7K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Burden of Symptomatic HEV-3 Infection in Southern Spain.

Alimentary pharmacology & therapeutics·2026
Same author

Adherence to Hepatocellular Carcinoma Surveillance Guidelines Among People with HIV and Chronic HBV Infection.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Safety and tolerability of switching to bictegravir/emtricitabine/tenofovir alafenamide versus continuing dolutegravir/lamivudine in people living with HIV with neuropsychiatric comorbidities: Week 24 and 48 results from the Management of INSTI-associated Neuropsychiatric Disorders (MIND) clinical trial.

International journal of antimicrobial agents·2026
Same author

ONWARD: A one health, pan-European multidisciplinary network advancing surveillance, research, clinical management and control of zoonotic hepeviruses.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology·2026
Same author

Rocahepevirus ratti: molecular evolution, zoonotic potential and public health impact.

Nature communications·2026
Same author

Circulating miRNA Signatures Associated with Atherosclerosis and Cardiometabolic Comorbidities in People with HIV.

Medical sciences (Basel, Switzerland)·2026

Related Experiment Video

Updated: Mar 19, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

13.9K

Current views on interferon therapy for HIV.

Antonio Rivero-Juárez1, Mario Frias1, Antonio Rivero1

  • 1a Infectious Diseases Unit, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC) , Hospital Universitario Reina Sofía de Córdoba, Universidad de Córdoba , Cordoba , Spain.

Expert Opinion on Biological Therapy
|June 11, 2016
PubMed
Summary

Interferon-alpha (IFN-alpha) showed early promise against HIV, but its use declined with HAART. Current research focuses on IFN-alpha's potential for eliminating the HIV viral reservoir.

Keywords:
HIVHIV reservoirPegylated interferoninterferon-alphaviral persistence

More Related Videos

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons
09:11

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons

Published on: August 23, 2016

21.6K
Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
12:03

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Published on: September 5, 2016

8.3K

Related Experiment Videos

Last Updated: Mar 19, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

13.9K
Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons
09:11

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons

Published on: August 23, 2016

21.6K
Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
12:03

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Published on: September 5, 2016

8.3K

Area of Science:

  • Immunology
  • Virology
  • Antiviral Therapy

Background:

  • Interferon-alpha (IFN-alpha) demonstrated early antiviral activity against Human Immunodeficiency Virus (HIV) without toxicity to peripheral blood mononuclear cells (PBMC).
  • Early clinical trials explored IFN-alpha's potential as an inhibitor of HIV replication.

Purpose of the Study:

  • To review the historical use of IFN-alpha in HIV treatment across various clinical settings.
  • To assess the evolving role of IFN-alpha in HIV therapy, particularly in the context of highly active antiretroviral therapy (HAART) and reservoir elimination.

Main Methods:

  • Review of historical studies on IFN-alpha in HIV treatment.
  • Analysis of IFN-alpha's efficacy in pre-HAART, structured treatment interruption (STI), acute HIV infection, salvage therapy, and HIV reservoir elimination strategies.

Main Results:

  • IFN-alpha's role in HIV therapy was largely dismissed with the advent of HAART due to its significant impact on reducing mortality and AIDS.
  • Promising results in eliminating the HIV viral reservoir suggest a potential resurgence of IFN-alpha research in this specific area.

Conclusions:

  • While IFN-alpha is no longer a primary antiretroviral agent, its efficacy in targeting the HIV viral reservoir presents a significant avenue for future research and therapeutic development.